title: Are solid tumor anti-idiotype vaccines ready for prime time? Commentary re: U. Wagner et al., Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti-idiotype antibody ACA125: immune responses and survival in palliative treatment. Clin. Cancer Res., 7: 1154-1162, 2001.
authors.affiliation: The Barrett Cancer Center, University of Cincinnati, Cincinnati, Ohio 45267-0502, USA. kenneth.foon@uc.edu
authors.forename: K A
authors.initials: KA
authors.lastname: Foon
authors.forename: M
authors.initials: M
authors.lastname: Bhattacharya-Chatterjee
mesh_terms: D000888:Antibodies, Anti-Idiotypic / Q000627:therapeutic use*; D019496:Cancer Vaccines / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007109:Immunity / Q000187:drug effects; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000276:immunology; D010166:Palliative Care
chemical_list: D000888:Antibodies, Anti-Idiotypic; D019496:Cancer Vaccines